NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/29/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,485.87 mln
Float58.38 mln
Earnings Date07/30/2026
EPS
4.19
Solid
P / E
23.71
Premium valuation
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.33
Borderline
1-Year Forecast
105
Modest upside
Relative Strength
71
/ 100
Outperforming
Business Description
Lantheus Holdings is a medical imaging and therapeutic company that develops and sells a broad range of products to help doctors detect and treat heart disease, cancer, and other conditions around the world. Its portfolio includes injectable agents for ultrasound and nuclear imaging, AI-powered software tools for assessing prostate cancer and Alzheimer's disease, and radiopharmaceutical therapies targeting advanced cancers. The company also has a growing pipeline of new diagnostic and treatment candidates developed in partnership with organizations such as GE Healthcare and Regeneron. Founded in 1956 and headquartered in Bedford, Massachusetts, Lantheus serves clinicians across multiple medical specialties.
